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Proteolytic remodeling of the extracellular matrix is an important Introduction 
aspect of the creation and progression of cancer. Matrix Invasion of cells from one rissue into a neighboring tissue 
metalloproteinases are important at several points during multi- occurs during many physiological processes, both normal 
stage neoplastic progression in tumor cells and responding and pathological. These include the invasion of blood 
blood vessels, inflammatory cells and stroma. vessels inro sites of tissue growth and inflammation, cell 
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migration during wound healing, embryo implantation, 
ovulation, involution of the mammary gland during lacta- 
tion, and the dissemination of tumors. In all of these 
processes the invading cells must breach barriers opposing 
their movement. These barriers include basement mem- 
branes, the stromal matrix, and cell-cell junctions. A 
common mechanism is believed to facilitate breaching 
of ail of these barriers during invasion, namely release of 
proteolytic enzymes from either the invading cells, the 
opposing and responding cells, or both. The types of pro- 
tejnases involved, the types of ceHs expressing them, 
and their precise roles are likely EO be different for differ- 
ent types of tissues and circumstances. Nevertheless, there 
are three classes of proteinases (matrix metalloproteinases, 
serine proteascs and cysteine proteases) that have altered 
distribution, increased expression and/or increased activity, 
during chcse processes, and are therefore believed to be 
involved in the matrix remodeling that facilitates invasion. 
The concept that tumorigenesis is a multistep process 
has been well documented and is widely accepted. His- 
torically, this has been thought to be exclusively a process 
of the progressive acquisition of mutations in key growth 
control genes, (oncogenes or tumor suppressor genes). 
Such mucations bestow upon cells traits associated with 
malignancy, for example, enhanced proliferation, invasive 
capability and the ability to grow in ectopic tissue envi- 
ronments. During tumor development, changing relation- 
ships between the premalignant and malignant cells 
and their microenvironment characterize all stages of the 
tumorigenic process. Although intrinsic factors are neces- 
sary for cellular transformation, extrinsic factors affecting 
the distribution, composition, and function of the extra- 
cellular matrix (ECM) into which a tumor expands, 
clearly make just as important a contribution to neoplas- 
tic progression and malignant conversion., Proteolyric 
enzymes are some of these extrinsic factors. It is signifi- 
cant that expression of the genes encoding these extrinsic 
facrors does not result directly from mutation. Instead, 
altered expression of the normal genes is part of the 
response of the tumor and host to the neopiastic process. 
Studies of proteolysis. in tumorigenesis have previously 
focused on basement membrane destruction during 
tumor invasion and metastasis. However, recent evidence 
suggests that proceinases, specifically matrix metallo- 
proteinases (MM&), are also involved in the earlier stages 
of tumor progression. 
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Table 1 
The matrix metalloproteinase multigene family. 
Matrix metalloproteinase EC name 
.---~~--11_ 
Substrates 
Minimal domain MMP 
Matrilysin (Pump-l) 
Hemapexin/vitronectin domain MMPs 
Simple-type 
Collagenase-1 (interstitial) 
Collagenase-2 (neutrophil) 
Collagenase-3 
Collagenase-4 
Metalloelastase 
Stromelysin-1 (transin) 
Stromelysin-2 
Furin activated-type 
Stromelyin-3 
Membrane-type MMP-I 
MMP-11 
MMP-14 
Membrane-type MMP-2 MMP-15 
Membrane-type MMP-3 MMP-16 
Membrane-type MMP-4 MMP-17 
Fibronectin-type 
Gelatinase A 
(72 KDa type IV coilagenase) 
Gelatinase B 
(92 KDa type IV collagenase) 
MMP-2 
MMP-9 
MMP-7 
MMP-1 
MMP-8 
MMP-13 
MMP-18 
MMP-12 
MMP-3 
MMP-10 
Proteoglycans, laminin, fibronectin, gelatins, collagen IV, 
elastin, entactin, tenascin 
Collagens, I, II, Ill, VII, X, gelatins 
Collagens I, II, Ill 
Aggrecan, collagen I, II, Ill, gelatins 
Collagen I 
Elastin, fibrinogen, fibronectjn 
Proteogtycans, laminin, gelatins, collagens III, IV, V, IX, 
Fibronectin, gelatins, entactin, SPARC, collagenase-1 
Proteoglycans, laminin, gelatins, collagen ill, IV, V, IX, 
Fibronectin 
Laminin, fibronectin, cyl mproteinase inhibitor 
Collagen I, It, Ill, fibronectin, vitronectin, proteoglycans, 
Progelatinase A, procoliagenase-3 
Progelatinase A 
Unknown 
Unknown 
Gelatins, collagens I, W, V, VII, X, fibronectin, elastin, 
Procollagenase-3 
Gefatins, collagens IV, V, eiastin 
EC name, enzyme commission nomenclature. Data from [1,4,5,47-501. 
Here we review the data suggesting that MM!% are 
involved in neoplasia, the tissue-specific expression pat- 
terns observed for MMPs during turnorigenesis and the 
mechanisms regulating their proteolytic activities, and the 
evidence suggesting that MMPs participate in neoplasdc 
progression at multiple points. 
The MMP multigene family 
The MMP multigene family currently has 1.5 members 
(Table 1). MMPs arc named for their catalytically active 
chelated zinc and calcium dependence, and are therefore 
characterized as metal-binding proteinases. There are 
MMP family members wirh enzymatic activity against 
virtually all components of the ECM and basement mem- 
branes. Most importantly, the MMP family includes the 
only enzymes capable of cleaving and denaturing fibrillar 
collagens. The compositions of the ECM and basemenr 
membrane vary depending on location, but generally 
include various forms of collagcns, glycoproteins (laminin, 
fibronectin, entactin, nidogen), proteoglycans, and glycos- 
aminoglycans. Penetration and/or degradation of base- 
ment membranes or ECM requires several different 
proceolytic activities because of their diversity in macro- 
molecular composition. Thus, during matrix remodeling, a 
complex cascade of proteolytic events occurs involving 
multiple MMP family members. 
MMP family members share many common features in 
addition to their zinc and calcium dependence. At the 
transcriptional level, MMPs are responsive to cytokines, 
growth factors, and hormones [ 11. Furthermore, changes 
in the pericellular environment that modify cell-ECM 
inreractions and/or composition of the ECM can confer 
differential expression of MMP mRNAs [ZJ]. 
MMPs share extensive sequence homology. The MMP 
family can be grouped and suhdivided based on the 
number and characteristics of specific functional protein 
domains, as shown in Figure 1 ([4]; Table 1). We now 
have some information about the functions of these 
domains. With the exception of matrilysin, all MMP 
family members concain a carboxy-terminal hemopexin/ 
vitronectin-like domain. This domain may have different 
functions in different MMP family members. In progelati- 
nase A and B ir is thought to tnediate interactions with 
specific proteinase inhibitors (discussed below); in colla- 
genasc-1 and -2, however, it is associated with inhibitor 
and substrate binding IS]. The hinge region, which links 
the hemopexin and catalytic domains, may be important 
in determining substrate specificity. Generally, the hinge 
region is variable in length and composition among family 
members, but MMPs that can degrade fibrillar collagens 
all contain a hinge of distinct size and composition 161. 
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Figure 1 
-I  
Minimal domain MMP 
Matrilysin 
Hemopexin/vitronectin domain MMPs 
(a) Simple-type 
Collagenase-l , -2, -3. -4, Metalloelastasa, Stromelysin-l , -2 
(b) Furin activated-type 
Stromelysin-3 
(c) Fibronectin-type 
Gelatinase A and B 
Domain structure of MMP family members. Classification of MMP 
family members based on functional domain structure. Catalytic, 
domain containing the catalytic active site and metal binding sites; 
F, furin-recognition domain; FN, domain containing homology to the 
collagen binding region of fibronectin; H, ‘hinge’ region linking catalytic 
and hemopexin domains; HpiVn, carboxy-terminal domain containing 
homology to hemopexin and vitronectin; Pre, domain containing signal 
sequence; Pro, a propeptide domain that is cleaved during activation; 
TMD, transmembrane spanning domain. Modified from [41. 
Structure-function studies have confirmed that the sub- 
strate specificicy is dictated by this region [7]. In all MMP 
family members the catalytic domain contains three con- 
served histidines. The structure of the full length active col- 
lagenase [S] confirms that the zinc contained in the catalytic 
site is coordinated by these conserved histidines. Gelatinase 
A and B do contain these conserved histidine amino acid 
residues, but also contain a 182-amino-acid insertion in this 
domain that is homologous to the collagen-binding region 
of fibronectin, and is required for collagen binding of 
gelatinasc A as well as cleavage 191. 
Table 2 
All MMPs are synthesized as inactive zymogens. Following 
activation (discussed below) MMPs are subject to further 
regulation by a family of naturally occurring inhibitor 
proteins termed tissue inhibitors of metalloproreinascs, or 
TIMI’s. To date, three human TIMPs (TIMP-1, TIMP-2, 
and TIMP-3) have been cloned [IO], and rhe existence of 
three additional MMP inhibitor proteins (imp-a, imp-b, 
and TIMP-4) has been reported ([ll]; Table 2). TIMPs 
bind either proMMPs or active MMPs with 1:l stoichiome- 
try, thereby inhibiting the autocatalytic activation of latent 
enzymes as well as the proteolytic capacity of active 
proteinases. ‘I’IMPs do, however, show some differences in 
their abilities to form complexes with MMPs. For example, 
TIMP-1 forms a tight complex with progelatinase B, 
whereas TIMP-2 instead forms a tight complex with prog- 
elarinase A. TIMPs can be proteolytically inactivated by 
diverse proteinases, for example neutrophil elastase (a 
serine proteinase) trypsin and stromelysin-3 [12]. MMPs 
can also be inhibited by noncovalent association with 
cu2-macroglobulin [13]. 
Activation of MMPs 
The zymogen forms of R/IMPS are inactive. Crystallographic 
studies have confirmed that this is due to coordinate bond- 
ing between the active site zinc atom and an unpaired 
cysteine thiol group located near the carboxyl end of MMP 
propeptides 1131. The primary mechanism for MMP activa- 
tion is interruption of the cysteine-zinc interaction, referred 
co as the cysteine switch ([14]; Fig. 2). In cell-fret systems, 
the cysteine-zinc atom interaction can be interrupted 
by organomercurials and chaocropic agents. Limited proteo- 
lysis of the propepcide also destabilizes the cysteine-zinc 
bond. Interruption of the cyst&e-zinc bond, by any 
means, results in conformational changes, opening ,the 
switch (Fig. 2). Following opening, autocatalytic or proteo- 
lytic cleavage of the remainder of the propeptide yields a 
truncated and catalytically competent enzyme. 
MMPs containing a furin-like recognition domain in their 
propeptides (stromelysin-3 and membrane-type MMPs 
(MT-MMPs)) are activated intracellrrlarly by a group of 
calcium-dependent transmembrane serine proteinascs of 
--_I_ 
The TlNlP multigene famiy 
- 
MMP inhibitor Molecular weight (x f 03) Target MMP 
- _I- _II- 
IMP-1 28.5 
TIMP”2 21 
TIMP-3 24-25 
TIMP-4 nt 
imp-a 29 
imp-b 30 
Collagenase-1, gelatinase B > gelatinase A >>> MT-MMP-1 
Gelatinase A > stromelysin-I, gelatinase 6, MT-MMP-1 
Gelatinase A = gelatinase B>MT-MMP-1 
unknown 
unknown 
unknown 
Nr, molecular weight has not been reported; >, activity towards protein to the left of symbol is greater than that towards protein to the right of symbol; 
z, equivalent activity towards both proteins. Data from [I ,4,5,47-501. 
. ~. 
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Figure 2 
/ 
2 
3 
(a) f& 
(b) 
Multistep activation of MMPs. (a) In the zymogen, the zinc ion is ligated 
by three histidines (H) in the catalytic domain and a cysteine in the pro- 
peptide. The cysteine switch mechanism of activation can be triggered in 
one of two ways. (b) Interaction of the cysteine with a thiol reagent (X), 
such as an organomercurial or certain chaotropic agents, produces a 
conformational change making the catalytic site accessible. This 
conformation may have enzymatic activity. Subsequently, the pro-peptide 
is removed by autocatalytic cleavage (see (d)). (c) A prote-olytic enzyme 
such as trypsin can also cleave the propeptide (f I trigger-ing a confor- 
mational change and activation of the cysteine switch. (d) An additional 
proteolytic step(s) which may be autocatalytic (Z), cleaves the remainder 
of the propeptide from either (b) or (c) making the MMP fully active. 
the subcilisin group termed furin/PACE/kex-Z-like pro- 
teinases (Fig. 3). MMPs without this recognition sequence 
are secreted in latent form. Serine proteinases, such as 
plasmin or urokinase-type plasminogen activator, elastasc 
and trypsin, cleave propeptide domains of secreted 
proMMPs and consequently induce autocatalytic activa- 
tion of collagenase-1, stromelysin-1 and gclatinase B; pro- 
gelatinase A is resistant to activation by serine proteinases. 
Some of the activated MMPs can further activate other 
proMMPs. For example, stromelysin-1 activates pro-colla- 
genase-1 and pro-gelatinase B 1151, whereas pro-gelatinase 
A is resistant to activation by other R/IMPS. Thus, serine 
proteinases are believed to be initiators for a complex 
array of activation cascades of proMMPs in akm 
Cell-mediated activation mechanisms are also possible, 
the model being activation of gelatinase A. This mecha- 
nism remained elusive until recently when several MT- 
MMPs, proceinases that span the plasma membrane, were 
discovered [S]. MT-MMPs are located in plasma mem- 
brane-associated ternary complexes. The prototype is the 
complex that contains progelacinase A, TIMP-2 and acti- 
vated MT-MMP-1 (Fig. 3). Activated MT-MMP-1 acts 
as a cell-surface receptor for TIMP-2. (MT-MMP-1 and 
TIMP-2 can also form a secreted binary complex [16]). 
The cell-surface form of the acdvatecl binary complex in 
turn acts as a receptor for progelatinase A, which binds via 
its carboxy-terminal hemopexjn domain [5,17]. MT-MMP- 
1 acrivicy is sensitive to inhibition by TIMP-2 and TZMP- 
3, but is not inhibited by TIMP-1 [18,19], the inhibitor that 
is most readily activated by inflammation [ZO]. Thus MT- 
MMP-1 could function as an activator of progelatinase and 
as a broad spectrum proteinase in the presence of high 
concentrations of TIMP-1. The facts Ehac MT-MMP-1 
is present in high concentrations in tumors and that it is 
insensitive co TIMP- 1 mean that widespread proteolysis of 
the ECM might be possible at tumor sites. A recent report 
suggests that gelatinase A may also be localized at the cell 
surface through interactions with an adhesion receptor [Zl]. 
MoscateIli and Rifkin [22] have proposed four possible 
advantages for having degradative enzymes in a bound 
state at the cell surface. First, bound proenzymes may be 
more readily activated and the bound enzymes generated 
may be more active than the same enzymes found in the 
soluble phase. Second, bound enzymes may be protected 
from activation by inhibitors. Third, binding enzymes to 
the cell surface may concentrate the components of a mul- 
tistep pathway, thereby increasing the rate of reactions. 
Fourth, immobilizing enzymes on the surface of a cell or in 
the matrix may provide a way td restrict the activity of the 
enzyme, so that only‘substrates in the vicinity of the cell or 
only adjacent matrix components are degraded. Localizing 
activation to the cell surface thus links MMP expression 
with protcolysis and invasion, and this may actually provide 
the most significant control point for MMP activity. 
MMP expression and neoplasia 
The association of MMPs with malignant transformation 
is well documented both in w&r0 and in Gwo [l]. Several 
MMPs were first cloned from tumor cell lines (gelatinase 
A, gelatinase B, collagenase-3, matrilysin, stromelysin-1, 
stromelysin-2, MT-MMP-1 and MT-M,MP-4), or as meta- 
stasis-specific genes from mecastatic tumors (scromelysin- 
3) [1,4,5]. In fact, expression of all members of the MMP 
family, whether constitutive or inducible, has been docu- 
mented in cultured ncoplascic cells from diverse develop- 
mental lineages ([1,23]; Table 3). MMPs have also been 
associated wick the malignant phenotype in a wide variety 
of human tissues, including lung, proscate, stomach, 
colon, breast, squamous carcinoma of the head and neck, 
melanoma and osteosarcoma. It is notable that two MMP 
family members are associated with poor clinical outcome: 
coIlagenasc-l expression in colorectal carcinoma [24] and 
stromelysin-3 expression in metastatic breast cancer [4]. 
There is increasing evidence that the expression pro- 
files for MMPs observed in cultured neoplastic cells are 
not representative of in ndvo situations. Neoplastic cells 
in culture express most members of the MMP family, 
either constitutively or following induction by oncogenes, 
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Figure 3 - 
Cell-surface activation of progelatinase A by 
MT-MMP. (a) The newly synthesized proMT- 
MMP-1 is activated by a furin-like enzyme 
intracellularly in the trans.Golgi network 
(TGN) to produce the active MT-MMP (b). 
(c) Active MT-MMP-1 then interacts with 
TIMP-2 and progelatinase A to form a trimole. 
cular complex (dh (e) The MT-MMP-1 then 
cleaves the progelatinase A tethered to the 
cell surface through MT&IMP and TIMP-2. 
(W (d) Progelatinese A (0) Gelatinase A 
MT-MMP-1 
+ 
(a) : .,,; >.>. 
’ y,:+, ,. 
proMT-MMP-1 
growth factors or cytakines (Table 3). These expression 
profiles have led investigators to speculate that expression 
of proteokytic enzymes by tumor cells was a critical step in 
the transformation process. In situ hybridization studies 
Table 3 
iblMP and TIMP expression in cultured neopiastic cells. 
-- 
MMP/TIMP Epithelial fibroblast Other mesenchymal - 
Matrilysin + nr nr 
Collagenase-t c + + 
Coliagenase-2 + + nr 
Collagenase-3 -t- + nr 
Metalloelastase nr nr + 
Stromelysin-I 4- + + 
Stromelysin-2 + + nr 
Stromelysin-3 c -I- + 
MT-MMP-1 + + + 
MT-MMP-2 + nr + 
MT-MMP-3 nr nr nr 
MT-MMP-4 + nr nr 
Gelatinase A + Jr + 
Gelatinase B + + f 
TIMP-1 “I- + + 
TIMP-2 -t + + 
l-IMP-3 + nr nr 
(+), Expression was detected by either northern analysis, immunocyto- 
chemistry, or zymography; nr, expression has not been reported in 
these cell types. Data from [I ,4,26,461. 
have revealed however, that expression of MMPs in 
tumors kn V&I is not limited to neoplastic cells, but fre- 
quently originates from tumor-associated stromal cells. 
For example, in carcinomas collagenasc-1, geiatinase A, 
getatinase B, metalloclastase, stromelysin-2, and strome- 
lysin-3 are expressed by various stromalcells, (acti+ated 
fibroblasts, macrophages, neutrophils, endothelial cells) 
(Table 4). On the other hand, expression of collagenase-3 
has only been observed in breast carcinoma cells; this 
enzyme was initially identified from a breast-tumor- 
derived cDNA library [25]. The ‘normal’ expression 
profile for collagenase-3 in humans is still undefined; in 
rodents it is widely expressed, particularly in bone. In car- 
cinomas of the colon, prostate, and lung, matrilysin mRNA 
is also expressed only in tumor cells. In breast carcinomas, 
however, matrilysin expression has been observed in both 
tumor and tumor-associated frbroblasts [Z]. There has 
been a recent report of matrilysin expression in an 
osteosarcoma, confirming that its expression is not limited 
to cells of epithelial origin [%I. Stromelysin-I expression 
has also been observed in both epithelial and mesenchy- 
ma1 cells, the expression being dependent on the stage 
and/or grade of the tumor. Stromelysin-1 is expressed in 
stromal fibroblasts in squamous cell carcinomas, although 
in the later stages of the disease, spindle cell carcinomas, 
its expression shifts to tumor cells [27]. As these cells are 
typically vimentin-positive and cytokcratin-negative, it is 
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likely that expression in the tumor cells reflects the ‘de- 
differentiated’ nature of the epithelial cells that have 
undergone epithelial/mesenchymal conversion [27]. 
These studies have several implications. Most notably, 
increased expression of MMP family members does corcc- 
late with ECM remodeling during tumorigenesis and with 
the malignant phenotype. With the exception of matrilysin, 
most MMPs appear to maintain spatial restriction r;91 w&o 
and are expressed either by stromal cells or by tumor cells 
hut typically not by both. Thus, the mechanisms regulating 
cell-type specificity in various types of tumors do not appear 
to be impaired as a consequence of neoplastic transforma- 
tion. The observation that the tumor-associated expression 
of MMPs in cultured cells is independent of lineage may 
result from the fact that culture environments fait to recapit- 
ulate the microenvironmental complexities present ila v&. 
Mechanism of induction of stromal MMPs 
The tissue specificity of MMP expression described above 
may have a role in determining where a MMP is expressed, 
but does nor explain why MMPs are often expressed in 
normal tissue that is adjacent to a tumor. Aside from 
soluble growth factors and inflammatory cytokines that 
induce MMP gene cxprcssion, are there other mechanisms 
regulating stromal expression of MMPs adjacent to tumor 
cells? There are several reported examples, where direct 
cell-cell conract between neoplastic and stromal cells in 
culture has resulted in MMP expression in either or both 
populations of cells [ZS]. Furthermore, alterations in cell 
shape, actin cytoskeleton and cellular interactions with 
integrins induces the production of certain MMPs in mes- 
enchymat cells [ZY]. Clearly the tumor stromal cells have 
different properties from quiescent fibroblasts [30]. 
Recently, Biswas and colleagues [31] demonstrated the 
existence of a soluble protein that is not a growth factor or a 
cytokine, named ‘collagenase stimulatory factor’, that is 
secreted by lung carcinoma cells. This novel protein coordi- 
nately induces the expression of collagenase-1, gelatinase A 
and stromelysin-1 in tumor-associated fibroblasts [30]. The 
idea that a tumor-cell-derived soluble &ctor might coordi- 
nately stimulate stromal MMP expression is supported by 
the observation that intensity of hybridization for MMP 
mRNAs in sL% decreases in stromal cells furthest away from 
tumor cells. The significance of this upregulation of MMP 
gene expression in the stromal compartment during tumor 
development and metastasis is underscored by the recent 
nbser vation indicating that ultraviolet light, which induces 
basal cell carcinomas in the skin, is a potent inducer of 
collagenase expression in the dermis in U& [32]. Thus, 
proteinases appear to be part of the ‘crosstalk’ between 
epithelial cells and adjacent stromai cells. 
Tumor growth, invasion and metastasis 
The functional evidence linking MMPs to primary tumor 
grawth, invasion, and metastasis historically comes from 
four main sources. There is correlative evidence showing 
that MMPs are expressed after transformation 2n vitro and 
in advanced stage tumors in Gwo. They appear important 
both in 8a n&u models of invasion and in ie Gw,o models of 
invasion and/or metastasis after injection into syngeneic or 
immunodeficient animals. And finally, transgenic mice 
ectopically overexpressing an MMP and/or a TIMP are 
altered in their ability to develop tumors. 
Transfection of specific MMPs into immortalized cells 
increases the tumorigenicity of the recipient cells [4], but 
overexpression of TTMPs in neoplastic cells decreases their 
tumorigenicity, suggesting that these natural inhibitors may 
function as natural suppressors of cellular invasion. Overex- 
prcssion of TIMP-2 in Ras-transformed rat embryo fibrob- 
lasts reduces their zpi zxuo growth rate and locally invasive 
character as well as reducing lung colony formation after 
intravenous injection in nude mice [33,34]. ‘I’IR/IP-1 also 
inhibits ila viva metastasis in animal models [l,lS], and dis- 
ruption of the gcnc for TIMP-1 by homologous recombina- 
tion increases invasive behavior and metastasis in Gvo [35]. 
Taken together, these studies suggest that the balance 
between ECM-degrading proteinases and their inhibitors is 
a key factor regulating growth, invasion, and metastasis of 
neoplastic cells i92 v&. 
TIM& also possess anti-angiogenic activities, suppress- 
ing vascularization of tumors and limiting primary tumor 
growth [3]. Nanomolar amounts of TlMP-2 block the 
angiogenic response to basic fibroblasc growth factor 
(bFGF), an important angiogenic cytokine produced by 
vascularized human tumors. Its ability to do this appears 
to be independent of its MMP inhibition activity. TIMP- 
1 and TIMP-2 also inhibit endothelial cell invasion of 
human amniotic membranes in odvo [3]. Apparently, 
TEMP-2 can inhibit the proliferation of human microvas- 
cular endothelial cells, whereas TIMP-1 can block inva- 
sion, by regulating proteolysis. The effects of TIMP-1 on 
endothelial cell invasion can be minimized by the addi- 
tion of antibodies that neutralize gelatinases [3]. 
Ectopic expression of MMPs in transgenic animal models 
suggests that MMPs and TIMPs are involved in neoplas- 
tic progression prior to malignant conversion as well as 
invasion and metastasis. The observation that MMPs are 
important in stromal-epithelia interactions in mammary 
development [36] suggested that a cransgenic model in 
which an auto-activating stromclysin-l (ST-l) gene was 
targeted to mammary epithelia would be informative, 
These animals show mammary hyperplasia in virgin 
animals, decreased mammary differentiation during preg- 
nancy and lactation, an enhanced stromal reaction in the 
involuting gland, and induction of hyperplasia, angiogene- 
sis, carcinoma J’H sits, and adenocarcinoma with age [37]. 
A remarkable feature of this model is that when ST-t 
overexpressing mice are intercrossed with transgenic mice 
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Table 4 
MMP and flMP expression in human carcinomas. 
MMPITIMP Neoplasia Localization 
- ~- - - 
Matrilysin Basal celt carcinoma Tumor epithelium 
Breast Tumor epithelium; stromal fibroblasts (focal) 
Colorectal Tumor epithelium 
Gastric Tumor epithelium 
Prostate Tumor epithelium 
Collagenase-1 Breast Tumor epitheli,um (focal), 
Stromal fibroblasts (tumor associated) 
Color&al Stroma 
Gastric Stromal fibrobtasts 
Head and neck Stromal fjbroblasts (tumor associated) 
Collagenase-2 Breast Not detected 
Cotlagenase-3 Breast Tumor epithelium (focal) 
Metalloelastase Breast Macrophages (isolated) and necrotic areas 
Stromelysin-1 Basal ceil carcinoma Stromal fibroblasts 
Breast Stromal fibroblasts (tumor associated) 
Colorectat Stromal cells 
Head and neck Stromal fibroblasts (tumor associated) 
Stromelysin-2 Breast Not detected 
Colorectal Not detected 
Head and neck Stromal fibroblasts (tumor associated) 
Strometysin-3 Basal celf carcinoma Stromal fibroblasts (tumor associated) 
Breast Stromal fibroblasts (tumor associated) 
Colorectal Stromal cells 
Head and neck Stromal fibroblasts (tumor associated) 
MT-MMP-1 Breast Stromal fibroblasts (diffuse) 
Colorectal Stromal cells 
Gastric Tumor epithelium 
Head and neck Stromal cells 
MT-MMP-4 Breast Positive expression by northern 
Gelatinase A Breast Stromal fibroblasts (focal) 
Colorectal Stromal fibroblasts (tumor associated) 
Head and neck Stromat cells 
Gelatinase B Breast Endothelial, macrophage, and inflammatory cells 
Colorectal Macrophages and inflammatory cells 
TIMP-1 Breast Tumor epithelium and stromal fibtoblasts (tumor associated) 
Colorectal Tumor epjthelium and stromal fibroblasts (tumor associatbd) 
Head and neck Tumor epithelium and tumor endothelium 
TIMP-2 &east Stromal cells 
Head and neck Stromal cells (focal) and tumor endothelium 
TIMP-3 Breast Stromal fibroblasts (tumor associated) 
Except for MT-MMP-4 ali data in table reflects mRNA expression as demonstrated by in situ hybridization. Data from [I ,4,24,25,51-561. 
constitutively or temporally overexpressing human TIMP- 
1, the ST-l phenotype is quenched [37,38]. Other animal 
models also suggest a role for MMPs in the early stages of 
tumor progression. For example, in mice in which tissue 
coliagenase is expressed in squamous epithelium [39], 
skin is hyperproliferative, developing hyperkeracosis and 
acanthosis. Although the animals do not develop malig- 
nant disease de nooo, they display an increased incidence 
of malignant conversion when treated with carcinogens 
compared to untreated littermates 1391. Following the 
observation that the expression of matrilysin is increased 
in the early stages of colorectal tumorigenesis, Matrisian 
and colleagues [40,41] intercrossed matrilysin-deficient 
mice with Min (multiple intestina1 neoplasia) mice that 
develop de ~DYO intestinal carcinomas as a direct result of a 
mumnt APC tumor suppressor gene. The resultant Min/ 
matrilysin-deficicpt mice develop 60% fewer intestinal 
tumors, suggesting that matrilysin is important in the 
development of lesions in this model [41]. Furthermore, in 
a transgenic model that develops metastatic s;luamous car- 
cinomas of the skin due to expression of human papillo- 
mavirus type 16 in basal keratinocytes, expression and 
activity of several MMPs and serine proteinases have been 
observed in 100% of animals at the dysplastic stage con- 
comitant with the onset of angiogenesis ([42], and our 
unpublished observations). Although only 20% of these 
animals go on to develop fully malignant disease, activa- 
tion of proteolytic enzymes at a pre-malignant stage sug- 
gests that they are involved in the onser of angiogenesis as 
well as malignant conversion. --. 
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The mechanism by which MMPs enhance metastacic com- 
petence of tumor cells appears to be straightforward; disso- 
lution of basement membranes and intersritial collagens 
facilitates the intravasation and exrravasation of tumor cells, 
thus promuring growth in cctopic tissue environments. The 
mechanism underlying the growth-promoting properties of 
MMPs remains unclear, but growth promotion may be an 
indirect effect of focal dissolution of the basement mem- 
brane. Loss of [he basement membrane has been shown to 
diminish the frequency of apoptotic cell death [36], alrer 
cell polarity [43] and increase the ability of cells to migrate 
[Z]. Furthermore, basement membranes are vast reservoirs 
of latent growth factors, such as bFGF or vascular endothe- 
lial growth factor (VEGF), that are probably released from it 
upon proceolysis. Constitutively increasing the local con- 
centration of growth factors would undoubtedty promote 
proliferation and subsequent invasion through a compro- 
mised basement membrane. Furthermore, our laboratory, 
among others (see [29] for review), has reported that bio- 
active fragments of ECM molecules produced through 
proteolysis can lead to upregulation of MMP gent expres- 
sion, thus allowing a vicious cycle of ECM degradation, 
neoplastic growth and tumor invasion to be initiated; these 
interactions may also stimulate cellular proliferation, alter 
apoptocic processes, and enhance viability of tumor cells. 
The inhibitory activities of the TIMPs may be most impor- 
tant when considering that proceolysis indirectly stimulates 
Figure 4 
proliferation. Hy maintaining the integrity of the ECM, 
proteinase inhibitors preserve the delicate balance that 
exists between tumor cells, matrix-bound growth factors 
and cytokincs, and matrix components. Consequently 
proceinase inhibirors could also have a marked cytostatic 
effect on tumors. It is important to remember that MMPs 
and TIMPs are also synthesized and secreted by normal 
cells in normal Eissue remodeling. In tumors MMP activity 
may be enhanced as a result of consticutive overexpression, 
constitucive activation, or loss of inhibition. Loss or impair- 
ment of regulation at any level in MMP biosynrhesis 
would compromise cellular homeoatasis and contribute to 
neoplascic progression. 
Are MMPs targets for cancer therapy? 
It is now evident that MMPs are broadly expressed during 
multistcp initiation and progression of solid tumors (Fig. 4). 
Several key steps in the progression to malignancy may 
directly involve MM&. First, after tumor initiation, MM15 
expressed by both cpithelial and stromal cells induce 
subtle modifications in the ECM. The resulting release of 
ECM-bound growth factors stimulates prohferation, a 
stromal response, and recruitment of inflammatory cells. As 
incipient neoplasia progresses, in addition to the ECM 
remodeling required for growth and expansion of the neo- 
plastic mass, new blood vessels must he recruited co facili- 
tate further growth [44]. Angiogenesis requires MMPs for 
capillary invasion and remodeling of connective tissue and 
(a) Normal (b) Initiation 
- 
(c) Angiogenesis 
(d) Malignant Conversion (e) Intravasation (f) Extravasation 
= Epithelisl cell 
= Fibroblast 
= inflammatory celi 
\ = Collagen k.....:i: = Basement membrane . . . . . . . 
= Capillary 
c 
= Proteolytic enzymes 
= Distant organ or lymph node 
--~~ -~-- 
Involvement of MMPs at several steps in 
malignant progression. (a) Under normal cir- 
cumstances, ECM turnover is a dynamic 
process where the net ratio between pro- 
teinases and inhibitors is balanced. (b) Follow- 
ing tumorigenic initiation MMPs expressed by 
neoplastic or responding stromat cells induce 
subtle alterations to ECM composition and 
turnover, stimulating release of ECM-bound 
growth or angiogenic factors, and recruitment 
of inflammatory cells. (c) Angiogenesis 
requires MMP action for capillary invasion and 
remodeling of connective tissue and for further 
release of latent angiogenic factors from ECM 
reservoirs. (d) As cells undergo malignant 
conversion, MMPs facilitate breaching of 
basement membranes and stromal invasion. 
(e) lntravasation and (f) extravasation further 
require MMP-stimulated proteolysis as tumor 
cells enter and exit the vasculature. 
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for release of the angiogenic factors that are also bound in a 
latent state to ECM and basement membrane reservoirs. 
As premalignant lesions undergv malignant conversion, 
MMPs are involved in breaching of basement membrane 
barriers. During metastasis, MMPs are involved in the 
invasive activity, intravasation and distant colonization. 
Any and all of these steps represent possible targets for 
therapeutic intervention. 
The ability of TIMPs, from tumor or stromal sources, 
to inhibit tumor growth in transgenic models has pro- 
vided a test of the concept that MMPs are potential thera- 
peutic targets. Indeed, several low molecular weight 
MMP inhibitors are already in clinical trials [34]. 
There are several possible ways to intervene in MMP 
action in cancer. The most obvious approach is to directly 
inhibit active MMPs. This approach would work for some 
tumors by limiting net proteolysis, but in some cases inhibi- 
tion of MMPs may also promote tumor growth. Some tumor 
cells grow better, GJ aiuo and in culture, in the presence of 
TIMPs [1,35]. Such tumors may be particularly sensitive to 
ECM composition l4.51. Moreover, inhibition of MMPs may 
also inhibit the beneficial effects of tumor-infiltrating lym- 
phocytes and macrophages, which use MMPs for extravasa- 
tion and invasion. Perhaps a more promising approach is to 
inhibit the activators of MMPs instead. These activators 
include other MMPs and cyst&e and serine proceinases 
[46]. By inhibiting the beginning of the activation cascade, 
one can more effectively reduce the total MMP activity 
generated. Another advantage is that the activation reac- 
tions appear to be localized at or near cell surfaces, where 
enzyme reactions (and their inhibition) become diffusion 
limited. In such zones, effective MMP concentrations are 
very high and ic is therefore difficult to inhibit the enzy- 
matic activity. If the MMP activators are directly inhibited, 
however, the effective MMP concentration can be signifi- 
cantly decreased inhibiting the vicious cycle described 
above. Thus, inhibition of an MMP at an early stage in 
tumor evolution may have profound effects on overall 
MMP expression. It remains to be determined whether car- 
cinomas, which primarily activate the stroma as the source 
of MMPs, or melanoma and fibrosarcomas, which actively 
produce MMPs, will represent better targets for therapy. 
Conclusion and perspective 
Solid tumors, unlike tumor cells in culture, are not homo- 
gcneous clusters of single cell types. Instead, they are a 
mixture of neoplascic cells and host-derived non-tumor 
stromal cells all interconnected and embedded in a 
dynamic ECM. As we are now beginning to understand, 
this amalgamation of cell types, each of which can express 
different proteinases, results in a complex pericellular envi- 
ronment containing a mixture of proteinases. In human 
tumors, MMP mRNAs have been found in stromal fibrob- 
lasts and vascular cells adjacent to clusters of malignant 
tumor cells, as well as in some tumor cells, depending on 
the enzyme in question and the type of tumor being exam- 
ined. On the other hand, MMP proteins are often associ- 
ated with tumor cells, suggesting that proteinases made by 
stromal cells near the invasive front localize to the tumor 
cells due to cell-surface receptors or local activation. Thus, 
activation at the cell surface may link MMP expression by 
stromal cells with invasion of tumor cells, and may actually 
provide the most significant control point in MMP activity. 
Hence, MMPs may be important in any one of multiple 
critical events in tumor evolution including neoplastic 
growth (by facilitating ECM degradation), proliferation (by 
releasing sequestered growth factors, such as bFGF, from 
ECM reservoirs), angiogenesis (by stimulating release of 
factors such as VEGF from the ECM), generation ofa reac- 
tive stroma, and promotion of tumor cell invasion of base- 
ment membranes as tumor cells enter and exit the vascu- 
lature during metastasis. 
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